Valdecoxib is a substance that is being studied as a treatment for pain and other side effects of cancer therapy. It belongs to the family of drugs called COX-2 inhibitors.
In view of the increased focus on alternative treatment options for people with arthritis, Pfizer is providing information to healthcare professionals about its COX-2 product Bextra® (valdecoxib).
COX-2 agents, with their perceived reduction in side effects, have contributed substantially to a dramatic increase in NSAIDs (non-steroidal anti-inflammatory drugs) prescription utilization and influenced the way physicians prescribe rheumatology medication
The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week.
EU regulators met with the marketing authorisation holder of Vioxx (rofecoxib), Merck Sharp & Dohme, on 4-5 October 2004 at the informal meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) held in Scheveningen, The Netherlands.